Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A blood biomarker for monitoring response to anti-EGFR therapy

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Hughes, NP, Xu, L, Nielsen, CH, Chang, E, Hori, SS, Natarajan, A, Lee, S, Kjær, A, Kani, K, Wang, SX, Mallick, P & Gambhir, SS 2018, 'A blood biomarker for monitoring response to anti-EGFR therapy' Cancer biomarkers : section A of Disease markers, vol. 22, no. 2, pp. 333-344. https://doi.org/10.3233/CBM-171149

APA

Hughes, N. P., Xu, L., Nielsen, C. H., Chang, E., Hori, S. S., Natarajan, A., ... Gambhir, S. S. (2018). A blood biomarker for monitoring response to anti-EGFR therapy. Cancer biomarkers : section A of Disease markers, 22(2), 333-344. https://doi.org/10.3233/CBM-171149

CBE

Hughes NP, Xu L, Nielsen CH, Chang E, Hori SS, Natarajan A, Lee S, Kjær A, Kani K, Wang SX, Mallick P, Gambhir SS. 2018. A blood biomarker for monitoring response to anti-EGFR therapy. Cancer biomarkers : section A of Disease markers. 22(2):333-344. https://doi.org/10.3233/CBM-171149

MLA

Vancouver

Author

Hughes, Nicholas P ; Xu, Lingyun ; Nielsen, Carsten H ; Chang, Edwin ; Hori, Sharon S ; Natarajan, Arutselvan ; Lee, Samantha ; Kjær, Andreas ; Kani, Kian ; Wang, Shan X ; Mallick, Parag ; Gambhir, Sanjiv Sam. / A blood biomarker for monitoring response to anti-EGFR therapy. In: Cancer biomarkers : section A of Disease markers. 2018 ; Vol. 22, No. 2. pp. 333-344.

Bibtex

@article{dd1ebbe9f1a34f7eb9b73e7679323a0f,
title = "A blood biomarker for monitoring response to anti-EGFR therapy",
abstract = "BACKGROUND AND OBJECTIVE: To monitor therapies targeted to epidermal growth factor receptors (EGFR) in non-small cell lung cancer (NSCLC), we investigated Peroxiredoxin 6 (PRDX6) as a biomarker of response to anti-EGFR agents.METHODS: We studied cells that are sensitive (H3255, HCC827) or resistant (H1975, H460) to gefitinib. PRDX6 was examined with either gefitinib or vehicle treatment using enzyme-linked immunosorbent assays. We created xenograft models from one sensitive (HCC827) and one resistant cell line (H1975) and monitored serum PRDX6 levels during treatment.RESULTS: PRDX6 levels in cell media from sensitive cell lines increased significantly after gefitinib treatment vs. vehicle, whereas there was no significant difference for resistant lines. PRDX6 accumulation over time correlated positively with gefitinib sensitivity. Serum PRDX6 levels in gefitinib-sensitive xenograft models increased markedly during the first 24 hours of treatment and then decreased dramatically during the following 48 hours. Differences in serum PRDX6 levels between vehicle and gefitinib-treated animals could not be explained by differences in tumor burden.CONCLUSIONS: Our results show that changes in serum PRDX6 during the course of gefitinib treatment of xenograft models provide insight into tumor response and such an approach offers several advantages over imaging-based strategies for monitoring response to anti-EGFR agents.",
author = "Hughes, {Nicholas P} and Lingyun Xu and Nielsen, {Carsten H} and Edwin Chang and Hori, {Sharon S} and Arutselvan Natarajan and Samantha Lee and Andreas Kj{\ae}r and Kian Kani and Wang, {Shan X} and Parag Mallick and Gambhir, {Sanjiv Sam}",
year = "2018",
doi = "10.3233/CBM-171149",
language = "English",
volume = "22",
pages = "333--344",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "I O S Press",
number = "2",

}

RIS

TY - JOUR

T1 - A blood biomarker for monitoring response to anti-EGFR therapy

AU - Hughes, Nicholas P

AU - Xu, Lingyun

AU - Nielsen, Carsten H

AU - Chang, Edwin

AU - Hori, Sharon S

AU - Natarajan, Arutselvan

AU - Lee, Samantha

AU - Kjær, Andreas

AU - Kani, Kian

AU - Wang, Shan X

AU - Mallick, Parag

AU - Gambhir, Sanjiv Sam

PY - 2018

Y1 - 2018

N2 - BACKGROUND AND OBJECTIVE: To monitor therapies targeted to epidermal growth factor receptors (EGFR) in non-small cell lung cancer (NSCLC), we investigated Peroxiredoxin 6 (PRDX6) as a biomarker of response to anti-EGFR agents.METHODS: We studied cells that are sensitive (H3255, HCC827) or resistant (H1975, H460) to gefitinib. PRDX6 was examined with either gefitinib or vehicle treatment using enzyme-linked immunosorbent assays. We created xenograft models from one sensitive (HCC827) and one resistant cell line (H1975) and monitored serum PRDX6 levels during treatment.RESULTS: PRDX6 levels in cell media from sensitive cell lines increased significantly after gefitinib treatment vs. vehicle, whereas there was no significant difference for resistant lines. PRDX6 accumulation over time correlated positively with gefitinib sensitivity. Serum PRDX6 levels in gefitinib-sensitive xenograft models increased markedly during the first 24 hours of treatment and then decreased dramatically during the following 48 hours. Differences in serum PRDX6 levels between vehicle and gefitinib-treated animals could not be explained by differences in tumor burden.CONCLUSIONS: Our results show that changes in serum PRDX6 during the course of gefitinib treatment of xenograft models provide insight into tumor response and such an approach offers several advantages over imaging-based strategies for monitoring response to anti-EGFR agents.

AB - BACKGROUND AND OBJECTIVE: To monitor therapies targeted to epidermal growth factor receptors (EGFR) in non-small cell lung cancer (NSCLC), we investigated Peroxiredoxin 6 (PRDX6) as a biomarker of response to anti-EGFR agents.METHODS: We studied cells that are sensitive (H3255, HCC827) or resistant (H1975, H460) to gefitinib. PRDX6 was examined with either gefitinib or vehicle treatment using enzyme-linked immunosorbent assays. We created xenograft models from one sensitive (HCC827) and one resistant cell line (H1975) and monitored serum PRDX6 levels during treatment.RESULTS: PRDX6 levels in cell media from sensitive cell lines increased significantly after gefitinib treatment vs. vehicle, whereas there was no significant difference for resistant lines. PRDX6 accumulation over time correlated positively with gefitinib sensitivity. Serum PRDX6 levels in gefitinib-sensitive xenograft models increased markedly during the first 24 hours of treatment and then decreased dramatically during the following 48 hours. Differences in serum PRDX6 levels between vehicle and gefitinib-treated animals could not be explained by differences in tumor burden.CONCLUSIONS: Our results show that changes in serum PRDX6 during the course of gefitinib treatment of xenograft models provide insight into tumor response and such an approach offers several advantages over imaging-based strategies for monitoring response to anti-EGFR agents.

U2 - 10.3233/CBM-171149

DO - 10.3233/CBM-171149

M3 - Journal article

VL - 22

SP - 333

EP - 344

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 2

ER -

ID: 55063159